“Cell Mediated Immune Responses Following Revaccination With An Influenza A/h5N1 Vaccine.”. Vaccine 34 (4). Vaccine: 547-554. doi:10.1016/j.vaccine.2015.11.055.
. 2016. “Comparison Of The Immunogenicity And Safety Of A Split-Virion, Inactivated, Trivalent Influenza Vaccine (Fluzone®) Administered By Intradermal And Intramuscular Route In Healthy Adults.”. Vaccine 29 (34). Vaccine: 5666-74. doi:10.1016/j.vaccine.2011.06.010.
. 2011. “Dose-Related Safety And Immunogenicity Of A Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine In Elderly Adults.”. J Infect Dis 193 (9). J Infect Dis: 1223-8. doi:10.1086/503050.
. 2006. “Higher Antigen Content Improves The Immune Response To 2009 H1N1 Influenza Vaccine In Hiv-Infected Adults: A Randomized Clinical Trial.”. J Infect Dis 205 (5). J Infect Dis: 703-12. doi:10.1093/infdis/jir837.
. 2012. “Immunogenicity And Safety Of Varying Dosages Of A Monovalent 2009 H1N1 Influenza Vaccine Given With And Without As03 Adjuvant System In Healthy Adults And Older Persons.”. J Infect Dis 206 (6). J Infect Dis: 811-20. doi:10.1093/infdis/jis427.
. 2012. “Phase Ii Trial In Adults Of Concurrent Or Sequential 2009 Pandemic H1N1 And 2009-2010 Seasonal Trivalent Influenza Vaccinations.”. Vaccine 33 (1). Vaccine: 163-73. doi:10.1016/j.vaccine.2014.10.083.
. 2015. “Priming Vaccination With Influenza Virus H5 Hemagglutinin Antigen Significantly Increases The Duration Of T Cell Responses Induced By A Heterologous H5 Booster Vaccination.”. J Infect Dis 214 (7). J Infect Dis: 1020-9. doi:10.1093/infdis/jiw310.
. 2016. “Randomized Clinical Trial Of A Single Versus A Double Dose Of 13-Valent Pneumococcal Conjugate Vaccine In Adults 55 Through 74 Years Of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine.”. Vaccine 36 (5). Vaccine: 606-614. doi:10.1016/j.vaccine.2017.12.061.
. 2018. “Randomized Trial Comparing The Safety And Antibody Responses To Live Attenuated Versus Inactivated Influenza Vaccine When Administered To Breastfeeding Women.”. Vaccine 36 (31). Vaccine: 4663-4671. doi:10.1016/j.vaccine.2018.06.036.
. 2018. “Safety And Immunogenicity Of A Subvirion Inactivated Influenza A/h5N1 Vaccine With Or Without Aluminum Hydroxide Among Healthy Elderly Adults.”. Vaccine 27 (37). Vaccine: 5091-5. doi:10.1016/j.vaccine.2009.06.057.
. 2009. “Vaccination Success Rate And Reaction Profile With Diluted And Undiluted Smallpox Vaccine: A Randomized Controlled Trial.”. Jama 292 (10). Jama: 1205-12. doi:10.1001/jama.292.10.1205.
. 2004.